GADOVIST 1.0 gadobutrol 18.1416g/30mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

gadovist 1.0 gadobutrol 18.1416g/30ml injection vial

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; hydrochloric acid; calcobutrol; water for injections - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

GADOVIST 1.0 gadobutrol 3.0236g/5mL injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

gadovist 1.0 gadobutrol 3.0236g/5ml injection syringe

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; trometamol; water for injections; calcobutrol - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

GADOVIST 1.0 gadobutrol 4.5354g/7.5mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

gadovist 1.0 gadobutrol 4.5354g/7.5ml injection vial

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; water for injections; hydrochloric acid; calcobutrol sodium - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

GADOVIST 1.0 Gadobutrol 9.0708g/15mL injection    vial Australia - English - Department of Health (Therapeutic Goods Administration)

gadovist 1.0 gadobutrol 9.0708g/15ml injection vial

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; calcobutrol sodium; water for injections; hydrochloric acid - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

GADOVIST 1.0 gadobutrol 4.5354g/7.5mL injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

gadovist 1.0 gadobutrol 4.5354g/7.5ml injection syringe

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; calcobutrol sodium; water for injections; hydrochloric acid - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

GADOVIST 1.0 gadobutrol 9.0708g/15mL injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

gadovist 1.0 gadobutrol 9.0708g/15ml injection syringe

bayer australia ltd - gadobutrol, quantity: 604.72 mg/ml - injection, solution - excipient ingredients: trometamol; water for injections; hydrochloric acid; calcobutrol sodium - this medicinal product is for diagnostic use only. gadovist 1.0 is indicated in adults and children including full-term newborns for: contrast enhancement in cranial and spinal magnetic resonance imaging (mri) contrast enhancement in whole body mri including head and neck region, thoracic space, breast, abdomen (pancreas, liver and spleen), pelvis (prostate, bladder and uterus), retroperitoneal space (kidney), extremities and musculoskeletal system use in first-pass mri studies of cerebral perfusion (see precautions) contrast enhancement in magnetic resonance angiography (ce mra) (see clinical trials) contrast enhancement in cardiac mri including assessment of rest and pharmacological stress perfusion and delayed enhancement

MAGNEVIST INJECTION 469 mgml Singapore - English - HSA (Health Sciences Authority)

magnevist injection 469 mgml

bayer (south east asia) pte ltd - gadopentetic acid, dimeglumine salt - injection - 469 mg/ml - gadopentetic acid, dimeglumine salt 469 mg/ml

MAGNEVIST SOLUTION Canada - English - Health Canada

magnevist solution

bayer inc - gadopentetate dimeglumine - solution - 469mg - gadopentetate dimeglumine 469mg - other diagnostic agents